AL 78898A

Drug Profile

AL 78898A

Alternative Names: AL-78898A; Compstatin analogue; POT-4

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania
  • Developer Alcon
  • Class Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Dry age-related macular degeneration

Most Recent Events

  • 23 Nov 2014 Apellis Pharmaceuticals enters into an agreement to acquire Potentia Pharmaceuticals
  • 15 Nov 2012 Alcon terminates a phase II trial for geographic atrophy associated with Age-related macular degeneration in USA (NCT01603043)
  • 30 Jun 2012 Phase-II clinical trials in Dry age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top